Last reviewed · How we verify

Acetaminophen Alone — Competitive Intelligence Brief

Acetaminophen Alone (Acetaminophen Alone) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-opioid analgesic. Area: Pain Management.

phase 2 Non-opioid analgesic COX-1 and COX-3 Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Acetaminophen Alone (Acetaminophen Alone) — Allodynic Therapeutics, Inc. Inhibits cyclooxygenase enzymes

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Acetaminophen Alone TARGET Acetaminophen Alone Allodynic Therapeutics, Inc phase 2 Non-opioid analgesic COX-1 and COX-3
BENZHYDROCODONE BENZHYDROCODONE marketed Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways 2018-01-01
Per Os Acetaminophen Per Os Acetaminophen Hospital for Special Surgery, New York marketed Non-opioid analgesic and antipyretic Cyclooxygenase (COX), primarily in central nervous system
Nefopam administration and prelevment Nefopam administration and prelevment University Hospital, Rouen marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter, dopamine transporter, serotonin transporter
néfopam néfopam University Hospital, Bordeaux marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter (NET); dopamine transporter (DAT); serotonin transporter (SERT)
Postop acetaminophen IV Postop acetaminophen IV AdventHealth marketed Non-opioid analgesic; antipyretic Cyclooxygenase (COX) enzymes
hydrocodone / acetaminophen extended release hydrocodone / acetaminophen extended release Abbott phase 3 Opioid agonist / non-opioid analgesic Opioid receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-opioid analgesic class)

  1. Allodynic Therapeutics, Inc · 1 drug in this class
  2. GlaxoSmithKline · 1 drug in this class
  3. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
  4. Muhammad Rahman Efendi Nasution · 1 drug in this class
  5. Nevakar, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Acetaminophen Alone — Competitive Intelligence Brief. https://druglandscape.com/ci/acetaminophen-alone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: